Oncoinvent ASA (CHIX:ONCINO) ROCE %: -158.27% (As of Dec. 2025)


CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr20,399.27
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA ROCE %?

Oncoinvent ASA CHIX:ONCINO 36 ROCE % is -158.27% as of Dec. 2025. GuruFocus rates CHIX:ONCINO with a GF Score™ of 36/100 and a GF Value™ of kr20,399.27. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oncoinvent ASA's annualized ROCE % for the quarter that ended in Dec. 2025 was -158.27%.

Oncoinvent ASA  (CHIX:ONCINo) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oncoinvent ASA ROCE % Related Terms

Oncoinvent ASA ROCE % Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA ROCE % Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.53 -127.30 -175.56 -116.50 -119.23

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -94.78 -110.68 -79.53 -114.18 -158.27
CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA ROCE % Calculation

Oncoinvent ASA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-155.047/( ( (171.015 - 57.939) + (204.958 - 57.959) )/ 2 )
=-155.047/( (113.076+146.999)/ 2 )
=-155.047/130.0375
=-119.23 %

Oncoinvent ASA's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-169.35/( ( (86.753 - 19.749) + (204.958 - 57.959) )/ 2 )
=-169.35/( ( 67.004 + 146.999 )/ 2 )
=-169.35/107.0015
=-158.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -158.27% mean?
Oncoinvent ASA (CHIX:ONCINO) has a ROCE % of -158.27% as of Dec. 2025.
Is Oncoinvent ASA's ROCE % too high?
Oncoinvent ASA's current ROCE % is -158.27%. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's ROCE % compare to VRTX and REGN?
Oncoinvent ASA's ROCE % of -158.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Oncoinvent ASA's current ROCE % is -158.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current ROCE % of -158.27%. The stock's GF Value™ is kr20,399.27, compared to a current price of kr1,039.91 — trading 94.9% below its estimated fair value. The current ROCE % is -158.27%. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current ROCE % is -158.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 94.9% below its estimated GF Value™ of kr20,399.27.

Key valuation signals for CHIX:ONCINO:

  • ROCE %: -158.27%
  • GF Value™: kr20,399.27 vs. price of kr1,039.91 (94.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr20,399.27
GF Value